• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK

Last Price$62.41Day Change (%)0.81%
Open Price$61.89Day Change ($)0.50
Day Range61.86–62.7352-Week Range47.97–64.00

As of Fri 9/30/2016 7:14:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck to Participate at the Morgan Stanley Global Healthcare Conference

    Merck to Participate at the Morgan Stanley Global Healthcare Conference

  2. Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

    Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

  3. UPDATE: Merck and Pfizer's diabetes treatment meets primary endpoint of late-stage trial

    UPDATE: Merck and Pfizer's diabetes treatment meets primary endpoint of late-stage trial

  4. Merck , Pfizer Diabetes Therapy Meets Late-Stage Study Goals

    Merck , Pfizer Diabetes Therapy Meets Late-Stage Study Goals

  5. BioNJ Announces Inaugural Patient Advocacy Summit for November 4

    BioNJ Announces Inaugural Patient Advocacy Summit for November 4

  6. Polycystic Ovarian Syndrome Therapeutics Report 2016 - Pipeline Review of 7 Companies & 9 Drug Profiles - Research and Markets

    Polycystic Ovarian Syndrome Therapeutics Report 2016 - Pipeline Review of 7 Companies & 9 Drug Profiles - Research and Markets

  7. FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck ’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients ...

    FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck ’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

  8. Merck scraps osteoporosis drug development on increased risk of stroke

    Merck scraps osteoporosis drug development on increased risk of stroke

  9. Bullish bias intact, U.S. benchmarks return to the range

    Bullish bias intact, U.S. benchmarks return to the range

  10. Bullish bias intact, U.S. benchmarks return to -2-

    Bullish bias intact, U.S. benchmarks return to -2-

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.